Find Octreotide Acetate manufacturers, exporters & distributors on PharmaCompass

Octreotide Acetate

Octreotide Acetate

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

42 API Suppliers, 25 USDMF, 5 CEP/COS, 4 JDMF, 5 EU WC, 1 KDMF, 18 NDC API, 24 Listed Suppliers

DEVELOPMENTS

21 Drug(s) in Development

21 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

DOSSIERs // Finished Dosage Formulations

181 Dossiers, 59 FDA Orange Book, 72 Europe, 7 Canada, 26 Australia, 2 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;INJECTION - EQ 0.05MG BASE/ML, INJECTABLE;INJECTION - EQ 0.1MG BASE/ML, INJECTABLE;INJECTION - EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 0.5MG BASE/ML, INJECTABLE;INJECTION - EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 0.05MG BASE/ML
INJECTABLE;INJECTION - EQ 0.1MG BASE/ML
INJECTABLE;INJECTION - EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INJECTION - EQ 0.5MG BASE/ML
INJECTABLE;INJECTION - EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers, 13 SPI Pharma, 3 Roquette, 2 Gangwal Chemicals, 2 Microlex e.U, 2 Kerry, 2 Gangwal Healthcare, 2 Actylis, 1 Pfanstiehl, 1 DKSH, 1 BASF, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Finar, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Rochem International Inc, 1 Sigachi Industries, 1 Ingredion Pharma Solutions

EXCIPIENTS BY APPLICATIONS

18 Fillers, Diluents & Binders, 10 Chewable & Orodispersible Aids, 10 Direct Compression, 9 Taste Masking, 6 Parenteral, 4 Co-Processed Excipients, 3 Disintegrants & Superdisintegrants, 3 Granulation, 2 API Stability Enhancers, 1 Thickeners and Stabilizers, 1 Topical

GLOBAL SALES INFORMATION

18 US Medicaid Prescriptions, 59 Finished Drug Prices

MARKET PLACE

13 APIs, 14 DOSSIERS // FDF

PATENTS

12 US Patents

12 US Patents

ANALYTICAL SOLUTION(s)

2 USP Standards, 6 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilations & Company Tracker #PharmaFlow, 36 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

294,453

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

150.00

Annual Reports

1,587.00

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Sandostatin, 79517-01-4, Nsc672461, Sandostatin (tn), Acetic acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-n-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, Octreotide acetate (usp)

Molecular Formula

C₅₁H₇₀N₁₀O₁₂S₂

Molecular Weight

1079.3 g/mol

InChI Key

XQEJFZYLWPSJOV-UHFFFAOYSA-N

A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.

1 2D Structure

Octreotide Acetate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

acetic acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

2.1.2 InChI

InChI=1S/C49H66N10O10S2.C2H4O2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41;1-2(3)4/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64);1H3,(H,3,4)

2.1.3 InChI Key

XQEJFZYLWPSJOV-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O.CC(=O)O

2.2 Synonyms

2.2.1 MeSH Synonyms

1. Compound 201 995

2. Compound 201-995

3. Compound 201995

4. Octreotide

5. Octreotide Acetate

6. Octreotide Acetate Salt

7. San 201 995

8. San 201-995

9. San 201995

10. Sandostatin

11. Sandostatine

12. Sandoz 201 995

13. Sandoz 201-995

14. Sandoz 201995

15. Sm 201 995

16. Sm 201-995

17. Sm 201995

18. Sms 201 995

19. Sms 201-995

20. Sms 201995

2.2.2 Depositor-Supplied Synonyms

1. Sandostatin

2. 79517-01-4

3. Nsc672461

4. Sandostatin (tn)

5. Acetic Acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-n-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

6. Octreotide Acetate (usp)

7. Schembl58453

8. Chembl2000504

9. Hms3748c05

10. Bcp04661

11. Nsc671663

12. Nsc-671663

13. Nsc-672461

14. Acetic Acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

15. D-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-[(1r,2r)-2-hydroxy-1-(hydroxymethyl)propyl]-l-cysteinamide Cyclic (2-7)-disulfide Acetate

16. 10-(4-aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-n-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide Acetate

17. D06495

18. 10-(4-aminobutyl)-19-[(2-amino-3-phenyl-propanoyl)amino]-16-benzyl-7-(1-hydroxyethyl)-n-[2-hydroxy-1-(hydroxymethyl)propyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

19. D-phenylalanyl-l-hemicystyl-l-phenylalanyl-d-trytophyl-l-lysyl-l-threonyl-l-hemicystyl-l-threoninol, Acetate

2.3 Create Date

2005-03-26

3 Chemical and Physical Properties

Molecular Formula	C₅₁H₇₀N₁₀O₁₂S₂
Molecular Weight	1079.3 g/mol
Hydrogen Bond Donor Count	14
Hydrogen Bond Acceptor Count	16
Rotatable Bond Count	17
Exact Mass	1078.46161005 g/mol
Monoisotopic Mass	1078.46161005 g/mol
Topological Polar Surface Area	420 Å²
Heavy Atom Count	75
Formal Charge	0
Complexity	1780
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	10
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Information

1 of 6
Drug Name	Octreotide acetate
Drug Label	Octreotide acetate injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered acetate solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octreotide acetate, known...
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market Status	Prescription
Company	Sun Pharm Inds; Teva Pharms Usa; Fresenius Kabi Usa; Sagent Pharms; Eurohlth Intl; Wockhardt Usa

2 of 6
Drug Name	Sandostatin
PubMed Health	Octreotide (Injection)
Drug Classes	Endocrine-Metabolic Agent
Drug Label	Sandostatin (octreotide acetate) Injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered lactic acid solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octre...
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market Status	Prescription
Company	Novartis

3 of 6
Drug Name	Sandostatin lar
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 30mg base/vial; eq 10mg base/vial; eq 20mg base/vial
Market Status	Prescription
Company	Novartis

4 of 6
Drug Name	Octreotide acetate
Drug Label	Octreotide acetate injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered acetate solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octreotide acetate, known...
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market Status	Prescription
Company	Sun Pharm Inds; Teva Pharms Usa; Fresenius Kabi Usa; Sagent Pharms; Eurohlth Intl; Wockhardt Usa

5 of 6
Drug Name	Sandostatin
PubMed Health	Octreotide (Injection)
Drug Classes	Endocrine-Metabolic Agent
Drug Label	Sandostatin (octreotide acetate) Injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered lactic acid solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octre...
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market Status	Prescription
Company	Novartis

6 of 6
Drug Name	Sandostatin lar
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 30mg base/vial; eq 10mg base/vial; eq 20mg base/vial
Market Status	Prescription
Company	Novartis

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Gastrointestinal Agents

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)

Antineoplastic Agents, Hormonal

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)

Market Place

Home

Post Enquiry

Market Place